Products

AI Workbench
Deep Genomics
Drug Discovery & Research
Deep Genomics is an AI-driven drug discovery company that decodes RNA biology to find novel targets, mechanisms, and molecules for RNA-based drug candidates, focusing on genetic diseases.

See all 1 product →

About Deep Genomics

Deep Genomics is a leading artificial intelligence (AI) therapeutics company that is revolutionizing drug discovery and development for genetic diseases. The company leverages a proprietary AI-powered discovery platform, known as the AI Workbench, which integrates machine learning algorithms with vast genomic data. This platform allows Deep Genomics to analyze billions of predictions across the human genome, for millions of genetic variants, and hundreds of millions of novel compounds, a level of productivity unattainable through traditional methods.

Deep Genomics’ core focus is on decoding RNA biology to identify novel therapeutic targets and develop innovative RNA-based treatments. Their technology helps accelerate the early stages of drug discovery and the design of RNA-based therapies, including oligonucleotides, RNA editing, and mRNA. They aim to develop precision therapies tailored to individual genetic profiles, with an initial focus on central nervous system (CNS) and metabolic diseases.

Focus Areas

genetic medicine RNA therapies artificial intelligence machine learning drug discovery genomics rare diseases metabolic disorders neurological conditions

Business Intelligence

TechnologyBioFM Platform (Biological Foundation Models), AI Workbench, BigRNA (proprietary BioFM)

What Physicians Need to Know

Genetic Medicine & RNA Therapies
Deep Genomics specializes in programming and prioritizing transformational RNA therapies for genetic conditions. They focus on developing steric blocking oligonucleotides (SBOs), which can both increase and decrease gene expression, offering more control than other RNA therapies.
Artificial Intelligence & Machine Learning
The company leverages AI and machine learning to decode RNA biology, identify novel targets for genetically defined diseases, and design therapeutic programs with a high success rate. Their AI Workbench platform is central to this process, enabling them to analyze vast amounts of data and predict the consequences of genetic mutations.
Drug Discovery
Deep Genomics aims to revolutionize drug discovery by using AI to move beyond traditional trial-and-error methods, reducing time and costs while improving precision and efficacy. They have successfully identified drug candidates for rare diseases like Wilson disease in significantly less time than traditional methods.
Genomics
Their work is rooted in human genomics, utilizing deep learning to interpret genetic mutations and identify therapeutic targets. They aim to translate genetic knowledge into life-saving medicines.
Rare Diseases
Deep Genomics is dedicated to developing drugs and therapies for rare and complex ailments that currently lack cures. They have active programs and partnerships focused on rare diseases, including Wilson disease, Niemann-Pick disease type C, and Frontotemporal Dementia.
Metabolic Disorders
The company is actively researching and developing preclinical therapies for metabolic disorders, with a focus on conditions like Wilson disease.
Neurological Conditions
Deep Genomics is advancing programs in neurodevelopmental and neurodegenerative disorders, including Frontotemporal Dementia and Niemann-Pick disease type C.
Physician Tip

Deep Genomics' AI-driven platform, particularly their BioFM Platform and BigRNA model, offers physicians the potential for genetically precise therapies for diseases currently without cures. Their approach can lead to faster identification of drug candidates and a higher preclinical success rate compared to traditional methods. This means a future with more targeted and effective treatment options for patients with genetic, metabolic, and neurological conditions, including rare diseases. The ability of their SBOs to both increase and decrease gene expression provides a versatile therapeutic approach. Physicians can anticipate a growing pipeline of AI-discovered RNA therapies addressing the root genetic causes of diseases.

Deep Genomics' platform, including the AI Workbench and BioFM Platform, is designed to integrate AI, software engineering, and RNA biology. They also offer GenomeKit, a tool to streamline genomic sequence analysis for researchers. Their strategy includes strategic partnerships with pharmaceutical companies to accelerate the R&D process and translate AI insights into viable therapeutics. Their technology stack includes Kubeflow, NetSuite, Keras, Microsoft Windows, Bash, Microsoft Azure, C++, and Python.

Products by Deep Genomics

1 product in the directory

AI Workbench
Deep Genomics
Drug Discovery & Research
Deep Genomics is an AI-driven drug discovery company that decodes RNA biology to find novel targets, mechanisms, and molecules for RNA-based drug candidates, focusing on genetic diseases.

Videos

News, demos, and interviews about Deep Genomics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Deep Genomics →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Deep Genomics utilizes an AI-driven platform to analyze vast amounts of genomic data and identify disease-causing genetic variations. This platform helps predict the impact of these variations and design novel RNA therapies that can correct or compensate for the genetic defects, thereby accelerating the drug discovery process for conditions like rare diseases, metabolic disorders, and neurological conditions.
Deep Genomics' drug discovery programs are focused on a range of genetic conditions, including various rare diseases, metabolic disorders, and neurological conditions. While specific program details and their exact status (e.g., preclinical, clinical trial phases) would require direct inquiry with the company, their platform is designed to be broadly applicable across diseases with a genetic basis.
Deep Genomics integrates compliance considerations throughout its drug discovery and development process. Their AI platform aims to identify drug candidates with favorable safety and efficacy profiles, which are crucial for regulatory approval. They likely work closely with regulatory bodies to ensure their novel RNA therapies meet all necessary guidelines and standards.
Deep Genomics' specific pricing structures for their genetic medicines would be determined upon successful development and market entry. These models often vary based on the therapeutic area, patient population size (especially for rare diseases), and the overall value proposition of the treatment. Direct engagement with Deep Genomics would be necessary for detailed pricing information.
Deep Genomics actively seeks partnerships with healthcare providers and research institutions to advance genetic medicine. These collaborations can range from research partnerships to explore new therapeutic targets or disease mechanisms, to potential programs aimed at improving patient access to their developing therapies. They likely offer scientific and potentially logistical support for such collaborations.
Deep Genomics leverages machine learning and AI to analyze vast and complex genomic datasets, allowing for the rapid identification of disease-causing genetic mutations and the prediction of their functional consequences. This capability significantly enhances the precision of drug target identification and streamlines the design of therapeutic molecules, thereby reducing the overall timeline for developing treatments for complex genetic disorders.
Deep Genomics' long-term vision is centered on transforming genetic medicine through its AI-driven platform, aiming to bring multiple innovative therapies to patients. Their stability is supported by ongoing research and development, strategic partnerships, and investment in their technology. Their ability to bring candidates to market will depend on the success of their clinical trials and regulatory approvals.

Investors

Who's funded Deep Genomics.

Related Companies

ClinicalTrials.gov is a publicly accessible website and online database of clinical research studies, managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). It serves as a central resource for patients, their families, healthcare professionals, and researchers to access comprehensive information on publicly and privately supported clinical studies across a […]

InsightRX is a science-first company that develops AI-powered precision medicine software for healthcare providers and life sciences organizations. Founded in 2015 by pharmacometricians, the company’s core mission is to optimize drug dosing for individual patients, moving beyond a ‘one-size-fits-all’ approach. Their platform integrates patient-specific data, quantitative pharmacology models, and machine learning to provide individualized dosing […]

Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]

Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]

ClinTrialMatch is an AI-powered digital health platform designed to optimize patient recruitment, enrollment, and retention in clinical trials. The platform aims to bridge the gap between patients seeking treatment options and clinical trials needing participants by leveraging AI-driven insights. It is currently an early-stage platform undergoing development and pilot collaboration. For physicians, ClinTrialMatch offers a […]

Evaxion Biotech is a pioneering clinical-stage TechBio company that leverages its proprietary, clinically validated, and scalable AI platform, AI-Immunology™, to decode the human immune system. This platform is used to discover and develop novel immunotherapies for cancer, infectious diseases, and increasingly, autoimmune diseases. The company’s mission is to transform patients’ lives by providing inventive and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.